XBIO - Xenetic Biosciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.21
+0.10 (+3.22%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.11
Open3.10
Bid3.01 x 800
Ask3.99 x 800
Day's Range3.01 - 3.28
52 Week Range1.37 - 8.95
Volume63,479
Avg. Volume777,379
Market Cap27.983M
Beta0.67
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Why Xenetic Biosciences Just Surged 28 Percent
    InvestorPlace2 days ago

    Why Xenetic Biosciences Just Surged 28 Percent

    Nanocap stocks are inherently risky in the stock market, but can certainly pay off for speculators when they go up. Xenetic Biosciences Inc. (NASDAQ:XBIO) surged 28%, up twofold from the $2 level the stock has been stuck at over the last year. At a closing price of $4.08 on Monday, Aug. 13, XBIO stock is still well below the $8.95 intraday high set in late-June.

  • ACCESSWIRE2 days ago

    Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Xenetic Biosciences, Inc. (XBIO), a clinical-stage biopharmaceutical company. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. In 2018, an estimated 63,000 cases of endometrial cancer will be diagnosed in the U.S., and an estimated 11,000 disease-associated deaths will occur.

  • ACCESSWIRE2 days ago

    Today’s Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announced last week that it would be working with Pfizer.

  • ACCESSWIRE2 months ago

    Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock

    Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.

  • Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Here’s How It Performed Recently
    Simply Wall St.3 months ago

    Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Here’s How It Performed Recently

    Understanding Xenetic Biosciences Inc’s (NASDAQ:XBIO) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...

  • How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns?
    Simply Wall St.6 months ago

    How Does Xenetic Biosciences Inc (NASDAQ:XBIO) Affect Your Portfolio Returns?

    If you are looking to invest in Xenetic Biosciences Inc’s (NASDAQ:XBIO), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare?
    Simply Wall St.7 months ago

    Xenetic Biosciences Inc (NASDAQ:XBIO): Is Now The Time To Bet On Healthcare?

    Xenetic Biosciences Inc (NASDAQ:XBIO), a USD$21.71M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • Does Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO Pay Compared Well With Peers?
    Simply Wall St.7 months ago

    Does Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO Pay Compared Well With Peers?

    Jeff Eisenberg took the helm as Xenetic Biosciences Inc’s (NASDAQ:XBIO) CEO and grew market cap to $16.72M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • Who Really Owns Xenetic Biosciences Inc (XBIO)?
    Simply Wall St.8 months ago

    Who Really Owns Xenetic Biosciences Inc (XBIO)?

    I am going to take a deep dive into Xenetic Biosciences Inc’s (NASDAQ:XBIO) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • Does Xenetic Biosciences Inc’s (XBIO) 83.8% Earnings Growth Make It An Outperformer?
    Simply Wall St.9 months ago

    Does Xenetic Biosciences Inc’s (XBIO) 83.8% Earnings Growth Make It An Outperformer?

    Assessing Xenetic Biosciences Inc’s (NASDAQ:XBIO) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...

  • Business Wire9 months ago

    Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update

    Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited financial results for the quarter ended September 30, 2017.

  • Business Wire9 months ago

    Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc

    Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has entered into a Right to Sublicense Agreement with Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH , wholly-owned subsidiaries of Shire plc .

  • Business Wire9 months ago

    Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer

    Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has appointed Jeffrey F.

  • How Should You Think About Xenetic Biosciences Inc’s (XBIO) Risks?
    Simply Wall St.10 months ago

    How Should You Think About Xenetic Biosciences Inc’s (XBIO) Risks?

    If you are a shareholder in Xenetic Biosciences Inc’s (NASDAQ:XBIO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Business Wire10 months ago

    Xenetic Biosciences Provides Update on Annual Meeting of Stockholders

    Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its 2017 Annual Meeting of Stockholders , scheduled for Thursday, October 5, 2017, will be rescheduled to a later date in 2017.

  • Business Wirelast year

    Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders

    Xenetic Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its 2017 Annual Meeting of Stockholders , scheduled for Wednesday, August 16, 2017, was convened and dismissed, without any business being conducted, due to lack of the requisite quorum....